

AleÅ; Å orf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1355189/publications.pdf>

Version: 2024-02-01

10
papers

144
citations

1307594

7
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

215
citing authors

#	ARTICLE	IF	CITATIONS
1	Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. <i>Toxicology and Applied Pharmacology</i> , 2022, 434, 115797.	2.8	4
2	ABCB1 as a potential beneficial target of midostaurin in acute myeloid leukemia. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 112962.	5.6	4
3	Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors. <i>Cancers</i> , 2020, 12, 1596.	3.7	13
4	S-(4-Nitrobenzyl)-6-thioinosine (NBMPR) is Not a Selective Inhibitor of Equilibrative Nucleoside Transporters but Also Blocks Efflux Activity of Breast Cancer Resistance Protein. <i>Pharmaceutical Research</i> , 2020, 37, 58.	3.5	4
5	Interactions between Maraviroc and the ABCB1, ABCG2, and ABCC2 Transporters: An Important Role in Transplacental Pharmacokinetics. <i>Drug Metabolism and Disposition</i> , 2019, 47, 954-960.	3.3	13
6	Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes. <i>Molecular Pharmaceutics</i> , 2019, 16, 4436-4450.	4.6	22
7	Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance. <i>Drug Metabolism and Disposition</i> , 2019, 47, 699-709.	3.3	15
8	Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters. <i>Biochemical Pharmacology</i> , 2019, 163, 290-298.	4.4	9
9	Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro. <i>Biochemical Pharmacology</i> , 2018, 154, 10-17.	4.4	41
10	In vitro and in silico Evaluation of Non-Quaternary Reactivators of AChE as Antidotes of Organophosphorus Poisoning - a New Hope or a Blind Alley?. <i>Medicinal Chemistry</i> , 2018, 14, 281-292.	1.5	19